[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644128":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":27,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":7,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":7,"enrollmentInfo":39,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":7,"overallStatus":47,"whyStopped":7,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":57},{"fullName":5,"class":6},"Sichuan University","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Xue Jianxin, MD. Phd","CONTACT","18982251798","killercell@163.com",[15],{"facility":16,"status":7,"city":17,"state":7,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":7},"West China Hospital of Sichuan University","Chengdu","610041","China","CN",{"type":22,"coordinates":23},"Point",[24,25],104.06667,30.66667,{"lat":25,"lon":24},{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","You Lu","MD. PhD","100644128","real-world-study-on-the-efficacy-safety-and-prognostic-factors-of-immune-checkpoint-inhibitors-combined-with-radiotherapy-in-patients-with-malignant-tumors-a-prospective-non-interventional-clinical-study-100644128",false,"NCT07665736","Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Histologically or cytologically confirmed malignant tumor;\n3. Planned to receive immunotherapy combined with radiotherapy as the basis of treatment;\n4. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);\n5. Adequate organ function (reference may be made to laboratory test indicators, such as routine blood tests, liver and kidney function);\n6. Voluntarily participate in this study, sign the informed consent form, and agree to comply with follow-up.\n\nExclusion Criteria:\n\n1. Patients with severe cognitive impairment, mental illness, or other conditions that, in the judgment of the investigator, preclude them from cooperating with participation in this study;\n2. Active, uncontrolled serious infection, or known human immunodeficiency virus (HIV) infection;\n3. Pregnant or breastfeeding women;\n4. Any unstable systemic disease (including but not limited to severe cardiac, hepatic, or renal insufficiency).","ALL","18 Years",{"count":40,"type":41},200,"ESTIMATED","OBSERVATIONAL","Currently, chemotherapy, targeted therapy, immunotherapy, and radiotherapy are the core treatment modalities for malignant tumors, with technologies advancing rapidly. Radiotherapy can induce massive tumor cell death in a short period and expose abundant tumor-specific antigens, turning the irradiated tumor into an endogenous tumor vaccine and even causing regression or disappearance of non-irradiated tumors (the abscopal effect) . Preclinical studies have shown that stereotactic body radiotherapy (SBRT) combined with PD-1\u002FPD-L1 inhibitors can activate systemic immunity, sensitize tumor-specific T cells to enter the bloodstream, and enable their homing to distant tumors, thereby inhibiting the growth of non-irradiated tumors . However, conclusions from rigorous randomized controlled trials have limitations when applied to the complex and heterogeneous patient populations in real-world settings. Real-world research is increasingly valued globally to complement traditional clinical trial evidence. This project prospectively collects data from patients receiving immunotherapy combined with radiotherapy in real-world clinical practice, which is of great value for evaluating long-term efficacy, safety, and impact on quality of life, and can provide high-level evidence for optimizing clinical practice and informing healthcare decisions.",[45,46],"Radiotherapy","Immune Checkpoint Inhibitors (ICIs)","NOT_YET_RECRUITING","2026-06-19",{"date":50,"type":51},"2026-06-24","ACTUAL",{"date":53,"type":41},"2026-06-30",{"date":55,"type":41},"2029-06-15",{"name":5,"class":6},1]